2. Search Result
Search Result
Results for "

monoacylglycerol lipase

" in MedChemExpress (MCE) Product Catalog:

29

Inhibitors & Agonists

3

Natural
Products

3

Recombinant Proteins

1

Antibodies

Targets Recommended:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-136562
    N-Arachidonyl maleimide

    		MAGL Metabolic Disease
    N-Arachidonyl maleimide is a potent, irreversible inhibitor of monoacylglycerol lipase (MAGL) with an IC50 value of 140 nM .
    N-Arachidonyl maleimide
  • HY-132310
    MAGL-IN-4

    		MAGL Neurological Disease
    MAGL-IN-4 is an orally active, selective and reversible monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 6.2 nM. MAGL-IN-4 can penetrate the blood-brain barrier (BBB). MAGL-IN-4 enhances endocannabinoid signaling mostly by the increase in the level of 2-AG via selective MAGL inhibition in the brain .
    MAGL-IN-4
  • HY-N1937
    Pristimerin
    3 Publications Verification

    Celastrol methyl ester

    		 Bacterial Cancer
    Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.
    Pristimerin
  • HY-108613
    JJKK 048
    1 Publications Verification

    		 MAGL Neurological Disease
    JJKK 048 is an ultrapotent and highly selective inhibitor of Monoacylglycerol lipase (MAGL).
    JJKK 048
  • HY-119283
    MAGL-IN-5
    1 Publications Verification

    CAY10499

    		 MAGL FAAH Metabolic Disease
    MAGL-IN-5 (CAY10499) is a non-selective lipase inhibitor with IC50 values of 144, 90, and 14 nM for human recombinant monoacylglycerol lipase(MAGL),hormone sensitive lipase(HSL), and fatty acid amide hydrolase(FAAH) respectively .
    MAGL-IN-5
  • HY-144375
    Monoacylglycerol lipase inhibitor 1

    		MAGL Others
    Monoacylglycerol lipase inhibitor 1 is a potent monoacylglycerol lipase inhibitor (compound 13) .
    Monoacylglycerol lipase inhibitor 1
  • HY-168032
    MAGL-IN-18

    		MAGL Inflammation/Immunology
    MAGL-IN-18 (compound 118) is a potent Monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 0.03 nM .
    MAGL-IN-18
  • HY-121517
    URB754

    		Others Neurological Disease
    URB754 is a potent inhibitor of the endocannabinoid-deactivating enzyme monoacylglycerol lipase (MGL) with an IC50 of 200 nM .
    URB754
  • HY-157041
    MAGL-IN-10

    		MAGL Cancer
    MAGL-IN-10 is areversible monoacylglycerol lipase (MAGL) inhibitor with very good ADME properties and low in vivo toxicity.MAGL-IN-10 can be used for the research ofcancer, neurological disorders and inflammatory pathologies .
    MAGL-IN-10
  • HY-116143
    MAGL-IN-12

    		MAGL Metabolic Disease
    SAR127303 is an orally active, selective, competitive monoacylglycerol lipase (MAGL) covalent inhibitor with IC50s of 3.8 nM and 29 nM for mouse and human MAGL, respectively. SAR127303 potently elevates hippocampal levels of 2-AG in mice. SAR127303 decreased long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus. SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. SAR127303 slows down epileptogenesis .
    MAGL-IN-12
  • HY-117632
    Elcubragistat
    1 Publications Verification

    ABX-1431

    		 MAGL Neurological Disease
    Elcubragistat (ABX-1431) is a highly potent, selective, and orally available, CNS-penetrant monoacylglycerol lipase (MAGL) inhibitor with an IC50 of 14 nM.
    Elcubragistat
  • HY-157038
    MAGL-IN-8

    		MAGL Inflammation/Immunology
    MAGL-IN-8 (compound 13) is a reversible monoacylglycerol lipase (MAGL) inhibitor, with an IC50 of 2.5 ± 0.4 nM for hMAGL .
    MAGL-IN-8
  • HY-163202
    MAGL-IN-13

    		MAGL Calcium Channel Neurological Disease Cancer
    MAGL-IN-13 (compound (3R, 4S) - 5v) is a selective, irreversible inhibitor for MAGL,with IC50 values of 0.026, 0.021 and 0.24 nM for mMAGL, hMAGL and rMAGL, respectively. MAGL-IN-13 can penetrant blood brain barrier. .
    MAGL-IN-13
  • HY-100792
    URB602

    		Bacterial Cancer
    URB602 is a selective monoacylglycerol lipase (MGL) inhibitor, which inhibits rat brain MGL with IC50 of 28±4 μM through a noncompetitive mechanism.
    URB602
  • HY-N1937R
    Pristimerin (Standard)

    		Bacterial Cancer
    Pristimerin (Standard) is the analytical standard of Pristimerin. This product is intended for research and analytical applications. Pristimerin is a potent and reversible monoacylglycerol lipase (MGL) inhibitor with an IC50 of 93 nM.
    Pristimerin (Standard)
  • HY-15250
    JZL195
    4 Publications Verification

    		 FAAH MAGL Autophagy Neurological Disease
    JZL195 is a selective and efficacious dual fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) inhibitor with IC50s of 2 and 4 nM, respectively .
    JZL195
  • HY-12332
    JW 642
    2 Publications Verification

    		 MAGL Neurological Disease
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.6, 14, and 3.7 nM for inhibition of MAGL in mouse, rat, and human brain membranes, respectively.
    JW 642
  • HY-120300
    UCM710

    		Cannabinoid Receptor Metabolic Disease
    UCM710 is an endocannabinoid (eCB) hydrolysis inhibitor that increases the levels of N-arachidonoyl ethanolamine and 2-arachidonoylglycerol in neurons. UCM710 inhibits fatty acid amide hydrolase and α/β-hydrolase domain 6, but not monoacylglycerol lipase .
    UCM710
  • HY-121476
    Arachidonoyl Serinol

    		MAGL Neurological Disease
    Arachidonoyl Serinol, an endogenous cannabimimetic metabolite, is an inhibitor of monoacylglycerol lipase (MAGL). Arachidonoyl Serinol inhibits the hydrolysis of [ 3H]2-oleoylglycerol and [ 3H]anandamide with IC50s of ～70 μM .
    Arachidonoyl Serinol
  • HY-120560
    OMDM169

    		Others Neurological Disease
    OMDM169 is a potent and selective monoacylglycerol lipase (MAGL) inhibitor with activity to increase 2-AG levels. OMDM169 exerts analgesic activity through indirect activation of cannabinoid receptors. The effective concentration of OMDM169 is 0.13 μM .
    OMDM169
  • HY-133130
    JNJ-42226314

    		MAGL Neurological Disease
    JNJ-42226314 is a competitive, highly selective and reversible non-covalent monoacylglycerol lipase (MAGL) inhibitor. JNJ-42226314 demonstrates dose-dependent enhancement of the major endocannabinoid 2-arachidonoylglycerol (2-AG) as well as efficacy in models of neuropathic and inflammatory pain .
    JNJ-42226314
  • HY-117474
    MJN110
    2 Publications Verification

    		 MAGL Neurological Disease
    MJN110 is an orally active and selective monoacylglycerol lipase (MAGL) inhibitor with IC50s of 9.1 nM and 2.1 nM for hMAGL and 2-arachidonoylglycerol (2-AG), respectively . MJN110 produces opioid-sparing effects and displays strong antihyperalgesic activity .
    MJN110
  • HY-146342
    FAAH/MAGL-IN-3

    		FAAH MAGL Neurological Disease
    FAAH/MAGL-IN-3 (Compound 10) is an irreversible fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) dual inhibitor with IC50 values of 179 and 759 nM against FAAH and MAGL, respectively. FAAH/MAGL-IN-3 shows low PAMPA (Parallel Artificial Membrane Permeability Assay) permeability .
    FAAH/MAGL-IN-3
  • HY-N0313
    Euphol

    		MAGL Endogenous Metabolite Inflammation/Immunology
    Euphol is a tetracyclic triterpene alcohol isolated from the sap of Euphorbia tirucalli with anti-mutagenic, anti-inflammatory and immunomodulatory effects, orally active. Euphol inhibits the monoacylglycerol lipase (MGL) activity via a reversible mechanism (IC50=315 nM). MGL inhibition in the periphery modulates the endocannabinoid system to block the development of inflammatory pain .
    Euphol
  • HY-119033
    MGL-IN-1

    		MAGL Inflammation/Immunology
    MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant .
    MGL-IN-1
  • HY-139182
    MAGL-IN-3

    		Endogenous Metabolite Metabolic Disease
    CAY10762 is an inhibitor of monoacylglycerol lipase (MAGL; IC50=34.1 nM). It reduces hydrogen peroxide-induced lactate dehydrogenase (LDH) release from Neuro2a cells when used at a concentration of 1 μM. CAY10762 (10 mg/kg) increases levels of 2-arachidonoyl glycerol in mouse brain.
    MAGL-IN-3
  • HY-111538
    MAGL-IN-1

    		MAGL Cancer
    MAGL-IN-1 is a potent, selective, reversible and competitive inhibitor of MAGL, with an IC50 of 80 nM. MAGL-IN-1 exhibits anti-proliferative effects against human breast, colorectal, and ovarian cancer cells. MAGL-IN-1 blocks MAGL in cell-based as well as in vivo assays .
    MAGL-IN-1
  • HY-116141
    7-Hydroxycoumarinyl arachidonate

    7-HCA; Umbelliferyl Arachidonate; 7-HC-arachidonate

    		 Phospholipase MAGL Others
    7-Hydroxycoumarinyl arachidonate (7-HCA) is a fluorogenic substrate of cytosolic phospholipase A2 (PLA2). 7-Hydroxycoumarinyl arachidonate is also a fluorogenic substrate for monoacylglycerol lipase (MAGL). MAGL protein catalyzes the hydrolysis of 7-Hydroxycoumarinyl arachidonat to generate Arachidonic acid (AA) and the highly fluorescent 7-hydroxyl coumarin (7-HC; HY-N0573). Release of 7-HC can be measured using a fluorometer .
    7-Hydroxycoumarinyl arachidonate
  • HY-121422
    JZP-361

    		MAGL Histamine Receptor Inflammation/Immunology
    JZP-361 is a potent, reversible and selective inhibitor of human recombinant MAGL (hMAGL) with an IC50 of 46 nM. JZP-361 also shows antihistaminergic activities and can be used for asthma research .
    JZP-361

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: